Vortioxetine effective for treatment of major depressive disorders finds study

In a new study published in Frontiers in Psychiatry, it was shown that vortioxetine is more effective in treating Major Depressive Disorder (MDD) in adults, although there is no discernible difference between it and serotonin noradrenaline reuptake inhibitors (SNRIs) and serotonin reuptake inhibitors (SSRIs) as a whole.

Major depressive disorder is characterized by poor self-esteem, low energy, lack of enjoyment, and a gloomy mood. The FDA granted vortioxetine its first license to treat MDD in adults in 2013. It is a novel antidepressant with multimodal activities and differs from other available treatments in terms of its pharmacological profile by both directly modulating 5-HT receptors and inhibiting the serotonin transporter. Xinyan Zhang and colleagues carried out this study in order to compare the effectiveness, acceptability, and tolerability of vortioxetine in the treatment of major depressive disorder in adults.

Using the keywords Vortioxetine, Trintellix, Brintellix, LuAA21004, mood disorder, major depressive disorder, affective disorder, and MDD, researchers searched Embase, PubMed, Web of Science, Cochrane Central Register of Controlled Clinical Trials (CENTRAL), and www.ClinicalTrials.gov for randomized controlled trials that compared vortioxetine to placebo or other antidepressants for the treatment of MDD from database in After deleting duplicates, 789 publications in total were identified. 20 appropriate randomized controlled trials were found after screening, and 19 of them were used in the final meta-analysis. Adults (18 years of age and older) with MDD as their major diagnosis were included.